July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” The summit aimed to speed up finding treatments for alopecia areata.
148 citations
,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
Baricitinib effectively regrows hair in severe alopecia areata cases.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
September 2025 in “International Journal of Innovative Technologies in Social Science” Biologic agents are effective for severe hidradenitis suppurativa when other treatments fail.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
47 citations
,
October 2014 in “Expert Opinion on Emerging Drugs” New alopecia treatments aim for better results and fewer side effects.
New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.
2 citations
,
November 2023 in “Frontiers in microbiology” The health of the gut may be important in developing new ways to prevent, diagnose, and treat alopecia areata.
2 citations
,
October 2025 in “Discover Immunity.” Alopecia Areata is an autoimmune disease causing hair loss, with no cure yet, but research may lead to new treatments.
1 citations
,
June 2025 in “Frontiers in Bioengineering and Biotechnology” Glycopeptide hydrogels are promising for tissue repair, drug delivery, and healing due to their multifunctional properties.
January 2026 in “Immune Network” Regulatory T cells adapt to different environments to control inflammation and support tissue repair.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
March 2017 in “Fundamental & Clinical Pharmacology” The model and estimator can predict drug exposure in kidney transplant patients well.
Baricitinib is more effective than methotrexate for severe alopecia areata.
26 citations
,
October 2016 in “Biomolecules & Therapeutics” 3-Deoxysappanchalcone helps human hair cells grow and stimulates hair growth in mice by affecting certain cell signaling pathways.
1 citations
,
October 2025 in “Nano Research” A new microneedle patch effectively treats atopic dermatitis by reducing skin stress and restoring immune balance.
22 citations
,
August 2017 in “Stem cells and cloning” Stem cell technologies and regenerative medicine, including platelet-rich plasma, show promise for hair restoration in treating hair loss, but more research is needed.
June 2016 in “Annals of the rheumatic diseases” Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.
59 citations
,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
3 citations
,
September 2023 in “Frontiers in immunology” Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.
191 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
December 2023 in “EPRA international journal of multidisciplinary research” Alopecia areata causes sudden hair loss, has genetic links, and can be managed but not cured.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
83 citations
,
June 2018 in “Frontiers in immunology” Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.